Abstract:An estimated 291 million people worldwide are living with hepatitis B virus (HBV) infection. Patients with chronic HBV infection are at an increased risk of developing liver cirrhosis and hepatocellular carcinoma (HCC), and about 1 million people died of hepatitis B and its related complications every year. Therefore, HBV represents a significant challenge to public health. The current HBV treatment regime mainly relies on nucleoside (acid) analogs (NUCs) and interferons (IFNs). NUCs inhibit the synthesis of viral DNA from genomic RNA by targeting the multifunctional reverse transcriptase. IFNs acts through both direct antiviral and indirect immunomodulatory effects. Due to the presence of covalently closed circular DNA (cccDNA), the template of HBV transcription, which are highly stable in the nucleus of host cells and difficult to be eliminated by licensed therapies, chronic HBV infection can't be cured virologically. Consistent efforts have to be made to develop a treatment regime that directly targets persistent cccDNA, inactivates or eliminates it to achieve a totally functional cure for chronic hepatitis B. The clustered regularly interspaced palindromic repeats (CRISPR)-Cas system is an acquired immune system found in prokaryotes. With the development of related research, the CRISPR-Cas9 gene editing system is rapidly becoming an efficient and potentially applicable therapeutic tool. The CRISPR-Cas9 system that specifically targets the conserved regions of the HBV genome, not only effectively inhibits viral replication but also is much simpler and more flexible than other gene editing tools, making it a very attractive treatment option. Numerous experimental studies have shown that the CRISPR-Cas9 system is able to disrupt free cccDNA, excise integrated HBV DNA, reduce pre-genomic RNA and a variety of viral proteins in vitro and in vivo. Furthermore, there are no detectable off-target effects and cytotoxic effects in these relevant anti-HBV studies. However, the feasibility and safety of the CRISPR-Cas9 system still face many challenges in clinical applications, including setting up a more ideal animal model, avoiding unintended off-target effects, achieving high efficiency and low immunogenicity in vivo delivery and establishing a platform of verification that adequately assesses possible risks. While many obstacles need to be overcome, the CRISPR-Cas9 system indeed enhances our ability to change the genome and brings new strategies for treating HBV infection. Besides, the CRISPR-Cas9 systems with better specificity continue to be developed, such as well-designed gRNA and new types or versions of Cas. Viral and no-viral vectors based on in vivo delivery methods for treatment continue to be innovated, and their therapeutic potential will continue to increase. In view of the powerful role on virus suppression of CRISPR-Cas9 technology and the lack of effective means of curing HBV, the CRISPR-Cas9 system still has a bright future in clinical research. This article will summarize the existing CRISPR-Cas9 systems in the study of anti-HBV, and try to explore its possible problems and potential solutions.

CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

Targeting Hepatitis B Virus Cccdna by CRISPR/Cas9 Nuclease Efficiently Inhibits Viral Replication

Inhibition of Hepatitis B Virus by CRISPR/Cas9 System via Targeting the Conserved Regions of Viral Genome.

CRISPR/Cas9 System with Dual Grnas Synergically Inhibit Hepatitis B Virus Replication

Application Of Crispr-Cas9 Gene Editing To Treat Hbv

Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV

Inhibition of Hepatitis B Virus Replication Via HBV DNA Cleavage by Cas9 from Staphylococcus Aureus

Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus

Cleavage of Intracellular Hepatitis B Virus Genomeby Using of CRISPR/Cas9

Co-delivery of Cas9 Mrna and Guide RNAs Edits Hepatitis B Virus Episomal and Integration DNA in Mouse and Tree Shrew Models

CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein expression

Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA

Dual Grnas Guided CRISPR/Cas9 System Inhibits Hepatitis B Virus Replication

Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9

Enhanced delivery of CRISPR/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy

The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer

Efficient Inhibition of Duck Hepatitis B Virus DNA by the CRISPR/Cas9 System.

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X

CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy